Peter is a life sciences executive with deep knowledge of the R&D productivity and sustainability challenges facing the industry. He has extensive experience in translating data and analytics into value-creating and optimizing strategies at the asset, franchise, and portfolio level, and he is an expert in characterizing and assessing risk and uncertainty. He has led process and organizational redesign efforts, integrating and collaborating across functions to improve both the speed and quality of decisions.
As VP, Head of Strategy at Alnylam Pharmaceuticals, Peter works closely with the leadership team to help shape the corporate strategy and long-range plans for the organization while maximizing its rich pipeline. His team also provides business planning and strategic support to the Program Teams responsible for bringing Alnylam’s new therapeutics to market.
Prior to joining Alnylam, Peter worked at Celgene Corp. as Executive Director, Corporate Strategy, where he supported senior leadership to shape and evolve the company’s corporate strategy and long-range plans, and provided frameworks, analytics, and insights on portfolio prioritization, innovation sourcing, and R&D strategy and productivity. Additionally, Peter worked at Bristol-Myers Squibb Co. as VP, R&D Strategic & Operational Portfolio Management, where he built an industry-leading capability in support of R&D budget planning, portfolio prioritization, and asset strategy that delivered a 5x improvement in ROI and $14B in value with minimal increased R&D investment. He crafted the vision for and led a 40+ staff function that tightly integrated development strategy with operational requirements, improving the speed and quality of portfolio decision making. He has also worked for Strategic Decisions Group, a boutique strategy consulting firm specializing in applied decision analysis, supporting clients in several high risk/high return industries faced with large scale investments amid great uncertainty, and for Mitsubishi Corporation, a leading Japanese sogo sosha, where he was Assistant to the President. Over the years he has built considerable expertise in business planning, asset development strategy, R&D portfolio strategy, transactions analysis, and corporate strategy.
He is fluent in Japanese, with extensive international/cross-cultural experience, and has a passion for identifying talent and cultivating its full potential through formal training/coaching and informal mentoring.